MTOR and cancer: Notably, the potential pro-inflammatory effect of PI3K-mTOR pathway inhibitors might offer advantages for cancer immunotherapy (Fruman et al., 2017), indicating that the C1 subtype might be suitable for PI3K inhibitors combined with ICB treatment.